
|Videos|June 25, 2013
Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer
Author(s)David D. Chang, MD, PhD
David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.
Advertisement
David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.
There are three TRINOVA studies, Chang says, which Amgen has been involved with for years. In the TRINOVA-1 trial, patients with ovarian cancer, primary peritoneal cancer, and fallopian tube cancer were randomized to receive trebananib (AMG 386) or placebo in combination with weekly paclitaxel chemotherapy.
Trebananib is a peptibody designed to block angiopoietins 1 and 2, and therefore blocking angiogenesis, Chang says.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5


































